[go: up one dir, main page]

AR061771A1 - Sistema de administracion terapeutica - Google Patents

Sistema de administracion terapeutica

Info

Publication number
AR061771A1
AR061771A1 ARP070102948A ARP070102948A AR061771A1 AR 061771 A1 AR061771 A1 AR 061771A1 AR P070102948 A ARP070102948 A AR P070102948A AR P070102948 A ARP070102948 A AR P070102948A AR 061771 A1 AR061771 A1 AR 061771A1
Authority
AR
Argentina
Prior art keywords
matrix
amounts
preferred
active ingredient
weight
Prior art date
Application number
ARP070102948A
Other languages
English (en)
Inventor
Luigi Bruschi Stefano De
Federico Mailland
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of AR061771A1 publication Critical patent/AR061771A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se expone matriz hidrofílica que comprende: a) al menos un derivado de ácido poliacrílico en cantidades preferidas de entre 0,5 y 40% b) al menos un éter de celulosa en cantidades preferidas de entre 30 y 9% y c) al menos un desintegrante en cantidades preferidas de entre 2 y 50% con respecto al peso de la matriz. Esta matriz se usa en combinacion con al menos un principio activo aceptable para su uso farmacéutico como por ejemplo ciclopiroxolamina, ciclopiroxi, para fabricar formulaciones de liberacion controlada solidas bioadhesivas para el tratamiento de desordenes vaginales, tales como candidiasis vulvovaginal, vaginosis bacterial o trichomoniasis. De acuerdo a una realizacion preferida, la matriz se usa en cantidades de entre alrededor de 5 y 60% y el principio activo en cantidades de entre alrededor de 2 y 70%, con respecto al peso de la formulacion.
ARP070102948A 2006-06-29 2007-06-29 Sistema de administracion terapeutica AR061771A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06116269A EP1872775A1 (en) 2006-06-29 2006-06-29 Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders

Publications (1)

Publication Number Publication Date
AR061771A1 true AR061771A1 (es) 2008-09-17

Family

ID=37433668

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102948A AR061771A1 (es) 2006-06-29 2007-06-29 Sistema de administracion terapeutica

Country Status (24)

Country Link
US (1) US8865201B2 (es)
EP (2) EP1872775A1 (es)
JP (1) JP5205374B2 (es)
KR (1) KR101443149B1 (es)
CN (2) CN103071157A (es)
AR (1) AR061771A1 (es)
AT (1) ATE455534T1 (es)
BR (1) BRPI0713298A2 (es)
CA (1) CA2652226C (es)
CO (1) CO6140022A2 (es)
CY (1) CY1109910T1 (es)
DE (1) DE602007004486D1 (es)
DK (1) DK2032123T3 (es)
EA (1) EA018257B1 (es)
ES (1) ES2339069T3 (es)
HR (1) HRP20100159T1 (es)
MA (1) MA30597B1 (es)
MX (1) MX2008016508A (es)
NO (1) NO20090095L (es)
PL (1) PL2032123T3 (es)
PT (1) PT2032123E (es)
RS (1) RS51279B (es)
SI (1) SI2032123T1 (es)
WO (1) WO2008000683A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
EP2163240A1 (en) * 2008-09-12 2010-03-17 Universita' Degli Studi Di Genova A method for the production of bioadhesive compact matrices
US20100105784A1 (en) * 2008-10-23 2010-04-29 Jean Paul Remon Pharmaceutical Pellets Comprising Modified Starch and Therapeutic Applications Therefor
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
EP2243482A1 (en) * 2009-04-20 2010-10-27 Polichem SA Use of nifuratel to treat infections caused by atopobium species
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP6680672B2 (ja) * 2013-10-10 2020-04-15 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 膣挿入されるエストラジオール薬学的組成物及び方法
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
CN105796520A (zh) * 2014-12-29 2016-07-27 四川滇虹医药开发有限公司 一种缓释型硝酸布康唑直压片剂及其制备方法
US10716305B2 (en) 2015-01-23 2020-07-21 Biocidium Biopharmaceuticals Inc. Anti-bacterial compositions
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
JP7219712B2 (ja) * 2016-10-13 2023-02-08 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 膣送達のための凍結乾燥医薬組成物
GB201808567D0 (en) * 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
CN109010320B (zh) * 2018-09-18 2021-09-14 浙江汇能生物股份有限公司 一种双释型聚卡波非钙颗粒剂及制备方法和畜禽中的应用
AR118580A1 (es) * 2019-04-05 2021-10-20 Gedea Biotech Ab Formulación de tableta vaginal
CN114129530A (zh) * 2021-12-08 2022-03-04 南京康川济医药科技有限公司 一种黄体酮缓释组合物及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096744A (en) * 1932-10-27 1937-10-26 Schering Corp Hydrogenation products of follicle hormones and method of producing same
US2232438A (en) * 1934-08-04 1941-02-18 Schering Corp Unsaturated pregnanolones and pregnandiones and a method of producing the same
US2243887A (en) * 1935-11-09 1941-06-03 Schering Corp Tertiary carbinols of the cyclopentano-polyhydrophenanthrene series and a method of producing the same
US2251939A (en) * 1935-11-22 1941-08-12 Schering Corp Tertiary alcohols of the cyclopentano polyhydro phenanthrene series and a method of producing the same
US2379832A (en) * 1936-06-02 1945-07-03 Schering Corp Process for the manufacture of unsaturated ketones of the cyclopentano polyhydro phenanthrene series
CH202847A (de) 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
US2265976A (en) * 1937-10-25 1941-12-09 Schering Corp Tertiary alcohols of the estrane series and their derivatives and a process for their manufacture
US2314185A (en) * 1939-09-01 1943-03-16 Zondek Bernhard Process for the manufacture of progesterone
BE665514A (es) * 1964-06-16
NL146838B (nl) * 1966-06-24 1975-08-15 Organon Nv Werkwijze voor het bereiden van (delta)5(10)-3- keto-19-norsteroiden.
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
WO2002000213A1 (en) 2000-06-23 2002-01-03 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
FR2813865B1 (fr) 2000-09-08 2002-12-20 Rexam Sofab Dispositif a buse unique pour la distribution selective de deux produits
CA2422424C (en) * 2000-09-19 2009-12-01 Cima Labs, Inc. Pharmaceutical compositions for rectal and vaginal administration
JP4959907B2 (ja) * 2001-03-27 2012-06-27 ワーナー チルコット（アイルランド）リミティド 抗菌剤投与のための膣内用ドラッグデリバリーデバイス
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
CN1302764C (zh) 2005-01-10 2007-03-07 凌沛学 一种妇科用药阴道凝胶片

Also Published As

Publication number Publication date
CY1109910T1 (el) 2014-09-10
DK2032123T3 (da) 2010-03-08
EA200900087A1 (ru) 2009-06-30
EP2032123A1 (en) 2009-03-11
EA018257B1 (ru) 2013-06-28
KR20090033341A (ko) 2009-04-02
DE602007004486D1 (de) 2010-03-11
HK1128587A1 (en) 2009-10-30
MX2008016508A (es) 2009-04-22
JP5205374B2 (ja) 2013-06-05
NO20090095L (no) 2009-01-07
CO6140022A2 (es) 2010-03-19
SI2032123T1 (sl) 2010-04-30
EP1872775A1 (en) 2008-01-02
PL2032123T3 (pl) 2010-06-30
ATE455534T1 (de) 2010-02-15
JP2009541419A (ja) 2009-11-26
MA30597B1 (fr) 2009-07-01
HRP20100159T1 (hr) 2010-05-31
US20110091555A1 (en) 2011-04-21
PT2032123E (pt) 2010-04-07
ES2339069T3 (es) 2010-05-14
WO2008000683A1 (en) 2008-01-03
BRPI0713298A2 (pt) 2012-04-17
CA2652226C (en) 2014-08-12
CN101478951A (zh) 2009-07-08
EP2032123B1 (en) 2010-01-20
KR101443149B1 (ko) 2014-09-23
CA2652226A1 (en) 2008-01-03
RS51279B (sr) 2010-12-31
CN103071157A (zh) 2013-05-01
US8865201B2 (en) 2014-10-21

Similar Documents

Publication Publication Date Title
AR061771A1 (es) Sistema de administracion terapeutica
JP5538434B2 (ja) 皮膚疾患を治療または予防するための、アベルメクチンまたはミルベマイシンとアドレナリン受容体との組合せ
BRPI0611400B8 (pt) formulações contendo xiloglicano muco-adesivas úteis em dispositivos médicos e em formulações farmacêuticas
BRPI0924460A2 (pt) composição farmacêutica para uso em oftalmologia médica e veterinária
ES2834985T3 (es) Composición que contiene cineol para administración nasal
AR062167A1 (es) Sistema de administracion gastrorretentivo
ES2620742T3 (es) Formulaciones de principio activo que contienen 2-tiazol-4il-1H-benzoimidazol (tiabendazol o TBZ) para la fabricación de WPC
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
ME01180B (me) Mukozni bioadhezivni nosač za sporo oslobađanje aktivnih supstanci
CO6150127A2 (es) Formulaciones de flibanserina y metodo para fabricarlas
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
CO6251360A2 (es) Bromhidrato de bupropion y aplicaciones terapeuticas
PE20091949A1 (es) Formulacion farmaceutica solida con liberacion retardada
PE20250018A1 (es) Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida
AR061790A1 (es) Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento
WO2007014124A3 (en) High drug load formulations and dosage forms
WO2007025182A3 (en) Drug compositions containing controlled release hypromellose matrices
SV2006001916A (es) Formulaciones farmaceuticas transdermales
WO2010029093A3 (en) Compositions for percutaneous administration
ECSP11010941A (es) Composición farmacéutica para el uso en el tratamiento de infecciones de transmisión sexual
WO2009008004A3 (en) Sustained release formulations of divalproex sodium
NZ703464A (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
PE20110923A1 (es) Formulaciones de desintegracion rapida pre-compactadas de compuestos con baja biodisponibilidad oral
CO6241114A2 (es) Composicion farmaceutica que comprende la combinacion del agente antimicrobiano ciprofloxacino y el agente antioxidante acido ascorbico para el tratamiento de infecciones urinarias

Legal Events

Date Code Title Description
FB Suspension of granting procedure